Progyny, Inc.
PGNYHealthcareNASDAQHealthcare Plans · Last scanned Oct 26, 2026
Scan Results
Daily timeframeProgyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. With a market capitalization of $2.22B, it sits in mid-cap territory. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists.
Market Cap
$2.22B
Beta
1.02
P/E (TTM)
30.82
P/E (Fwd)
12.52
EPS (TTM)
$0.94
EPS (Fwd)
$2.31
ROE
16.2%
ROA
10.1%
Cash
$236.9M
Total Debt
$27.0M
Free CF
$196.5M
52W Change
48.3%
Annual Financials
Cash vs Debt
Where PGNY stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PGNY finished 11.58% above its 150-day moving average ($24.95) and 14.66% above its 200-day moving average ($24.28). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PGNY overbought or oversold?
At the October 20, 2026 close, PGNY's RSI(14) was 71.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Progyny, Inc. holds $236.9M in cash against $27.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $196.5M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 16.2%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.1% further supports the picture of efficient asset utilization. Revenue has grown from $786.9M (2022) to $1.29B (2025), reflecting a 64% increase over the period.
With cash comfortably exceeding debt, PGNY has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Progyny, Inc. and its sector.